Biosimilars And Non-innovator Biotherapeutics In MENA Region: Opportunities And Challenges | 13772
Pharmaceutical Regulatory Affairs: Open Access
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Biotherapeutics are becoming popular for treating a wide range of life threatening diseases and representing a growing segment
of pharmaceutical industry. These products are among the most expensive healthcare products. The use of biosimilars has the
potential to reduce healthcare cost. The aim of the current work is to examine the regulatory framework for approving biosimilar
products in the Middle East and North Africa (MENA) region and discuss the opportunity and challenging of biosimilars in this
MENA region can be considered as the most influential and attractive pharmaceutical markets among other emerging
markets. The current study review, examine and compare regulatory guidelines for biosimilar products approval from Jordan and
Saudi Arabia as an example from regulatory authorities in MENA. We examine the published guidelines form Saudi Food and
Drug Authority (SFDA) and Jordan Food and Drug Administration (JFDA).
Health care expenditure in MENA region is increasing over the recent years and the pharmaceutical market is expected to
grow to become one the leading region among emerging markets. All of MENA countries spent less that 10% of its GDP on health
care expenditure. This percentage is expected to rise within the next few years to make the area more attractive for biosimilar
investment. But the regulatory framework for biosimilar in most of these countries is still underdeveloped. Another challenge
that will face biosimilar manufacturers is that the pricing strategy for biosimilars is not yet developed.
Ibrahim Aljuffali is an assistant Professor at the Department of Pharmaceutics, College of Pharmacy, King Saud University. Dr. Aljuffali earned his
PhD degree from the University of Georgia (UGA). Dr. Aljuffali also earned a graduate diploma in Pharmaceutical & Biomedical Regulatory Affairs,
graduate diploma in Clinical Trials Design & Management and currently is a candidate for a Master of Science Degree in Pharmacy with an emphasis
in Regulatory Affairs from UGA. Dr. Aljuffali is currently the Director of Regulatory Science Research Unit, Vice Dean for Development and Quality
and a Consultant to the President of Saudi Food and Drug Authority.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals